Vural Özkan, Yılmaz Özcan, Gedikli Ömer, Taş Alperen
Department of Cardiology, Ahi Evran University Training and Research Hospital, Kırşehir, Turkey.
Department of Cardiology, Ondokuzmayıs University Medicine Faculty, Atakum, Turkey.
Acta Cardiol. 2025 Aug;80(6):623-630. doi: 10.1080/00015385.2025.2511519. Epub 2025 Jun 3.
Infective endocarditis is defined as an infection of the endothelial surfaces in the heart (valves and endocardium), prosthetic heart valves, and intracardiac devices (such as pacemaker leads and ventricular assist devices). Due to diagnostic challenges, determining the true incidence of infective endocarditis is difficult. Despite advancements in diagnosis and treatment, incidence and mortality rates have not decreased. In this study, we evaluated the clinical and laboratory parameters of patients with infective endocarditis followed in our hospital between 2005 and 2018 and assessed their relationship with in-hospital and one-year mortality.
This study retrospectively analysed 145 patients aged ≥18 years who were diagnosed with infective endocarditis and followed in our hospital between 2005 and 2018. Data were analysed using IBM SPSS V23. Statistical analyses included the Shapiro-Wilk test, T-test, Mann-Whitney U test, and Chi-square test.
The average age of the patients was 53 (18-86), and 52.4% ( = 76) were male. In 34% ( = 37) of our patients, the predisposing factor for infective endocarditis was rheumatic valve disease. In-hospital mortality was 31.7%, and one-year mortality was 40.6%. A statistically significant difference in in-hospital mortality was found between combination therapy (23%) and medical therapy (40.8%). Mitral valve involvement was the most common, occurring in 48.3% of patients. Staphylococci were the most frequently isolated microorganisms in blood cultures (41.4%). Heart failure was the most common complication and was associated with the highest mortality rate (23.4%). NYHA was an independent predictor of in-hospital mortality.
In our study, surgical intervention, i.e. combination therapy, applied after two weeks of antibiotic treatment, was found to be more effective. Early combination therapy may be life-saving.
感染性心内膜炎被定义为心脏(瓣膜和心内膜)、人工心脏瓣膜及心内装置(如起搏器导线和心室辅助装置)的内皮表面感染。由于诊断存在挑战,确定感染性心内膜炎的真实发病率很困难。尽管在诊断和治疗方面取得了进展,但发病率和死亡率并未下降。在本研究中,我们评估了2005年至2018年在我院接受治疗的感染性心内膜炎患者的临床和实验室参数,并评估了它们与住院死亡率和一年死亡率的关系。
本研究回顾性分析了2005年至2018年在我院诊断为感染性心内膜炎并接受治疗的145例年龄≥18岁的患者。使用IBM SPSS V23对数据进行分析。统计分析包括Shapiro-Wilk检验、T检验、Mann-Whitney U检验和卡方检验。
患者的平均年龄为53岁(18 - 86岁),52.4%(n = 76)为男性。在我们的患者中,34%(n = 37)感染性心内膜炎的诱发因素是风湿性瓣膜病。住院死亡率为31.7%,一年死亡率为40.6%。联合治疗(23%)和药物治疗(40.8%)之间的住院死亡率存在统计学显著差异。二尖瓣受累最为常见,发生在48.3%的患者中。葡萄球菌是血培养中最常分离出的微生物(41.4%)。心力衰竭是最常见的并发症,且与最高死亡率(23.4%)相关。纽约心脏协会(NYHA)分级是住院死亡率的独立预测因素。
在我们的研究中,抗生素治疗两周后进行的手术干预,即联合治疗,被发现更有效。早期联合治疗可能挽救生命。